Genetic Testing Recommendation
You need germline multigene panel testing performed on a blood sample, which should include at minimum: MLH1, MSH2, MSH6, PMS2, EPCAM, PTEN, BRCA1, and BRCA2. 1
Why You Meet Testing Criteria
Your clinical scenario clearly meets multiple criteria for genetic evaluation based on the most current NCCN guidelines 1:
- Personal history of colorectal cancer combined with family history of Lynch syndrome-related cancers (breast and endometrial cancer in first-degree and second-degree relatives)
- Your daughter's breast cancer diagnosis represents a first-degree relative with an LS-related cancer
- Two aunts with endometrial and breast cancer represent second-degree relatives with LS-related cancers
This pattern raises concern for Lynch syndrome (which accounts for ~3% of colorectal cancers and causes increased risk for colorectal, endometrial, breast, ovarian, gastric, and other cancers) 1, as well as hereditary breast-ovarian cancer syndrome given the clustering of breast and endometrial cancers in your family.
Blood Sample vs. Tumor Biopsy
The test should be performed on a blood sample (germline testing), not just tumor biopsy 1, 2. Here's the optimal testing algorithm:
Step 1: Tumor Testing First (If Available)
If your colon tumor tissue is available, it should first undergo:
- Immunohistochemistry (IHC) for mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) and/or
- Microsatellite instability (MSI) testing 2
This tumor testing helps guide which genes to prioritize but does not replace germline blood testing 3.
Step 2: Germline Blood Testing
Regardless of tumor testing results, you need germline genetic testing from a blood sample because:
- Blood testing identifies inherited mutations that affect your entire body and can be passed to children
- Tumor testing alone can miss hereditary syndromes (5-10% false-negative rate with IHC) 2
- Your family history pattern warrants germline evaluation even without tumor results 1
Specific Genes to Test
Minimum essential genes 1:
- Lynch syndrome genes: MLH1, MSH2, MSH6, PMS2, EPCAM
- Hereditary breast-ovarian cancer genes: BRCA1, BRCA2
- Other relevant genes: PTEN
Additional genes to consider 1:
- POLD1, POLE (associated with colorectal and endometrial cancer risk)
Many laboratories now offer comprehensive multigene panels testing 20+ genes simultaneously, which may identify additional actionable findings in 9.4% of colorectal cancer patients that wouldn't be detected by limited testing 4.
Critical Pitfalls to Avoid
Don't rely solely on tumor testing: Even if tumor shows normal mismatch repair proteins, you still need germline blood testing given your family history 2
Don't test only BRCA1/2: Studies show that 67% of patients meeting BRCA testing criteria have mutations in OTHER genes 5. Your pattern requires broader Lynch syndrome gene testing.
Don't delay testing: 34.5% of Lynch syndrome patients would be missed without multigene panel testing 1, and early identification allows for cancer prevention in you and your relatives.
Ensure genetic counseling: Pre-test counseling by a genetics professional is essential to understand implications, and post-test counseling is critical for interpreting results and cascade testing of family members 3.
Why This Matters for Your Family
- If a pathogenic variant is found, your daughter and other relatives should undergo predictive genetic testing for the specific familial mutation 2
- This enables targeted surveillance and risk-reducing interventions that can prevent cancer or detect it early
- Lynch syndrome carriers have up to 60% lifetime risk of endometrial cancer and require specific surveillance protocols 1
The testing should be ordered through a genetic counselor or physician experienced in hereditary cancer syndromes, as proper interpretation and family cascade testing are essential components of care 3.